

Effect of blood-flow restriction on platelet-rich plasma composition

Submission date 15/04/2024	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 24/04/2024	Overall study status Completed	<input checked="" type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 05/11/2025	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Blood-flow restriction therapy is an exercise in which tourniquets are used on the upper and/or lower limbs to partially restrict the muscle's blood flow. This stimulates a stress environment in the muscle that, combined with low-load exercise, has been linked with similar strength and hypertrophy (muscle growth) gains to traditional weight training. The tourniquets restrict 80% of the blood flow for about 5 minutes, using around 30% of the load regularly used for the exercise.

The molecules IL-6 and IGF-1 are typically released during exercise and are related to the muscle changes resulting from exercise/training (increased strength, endurance, and volume). Scientific studies have demonstrated that different types of exercise (aerobic, weights, etc) result in different changes in these molecules. The aim of this study is to determine how blood-flow restriction therapy could change the levels of IL-6 and IGF-1 in plasma (the fluid part of the blood). The changes of these molecules in the plasma caused by the blood-flow restriction therapy could be translated in the future to treat some diseases or injuries with substances produced by our bodies.

Who can participate?

Healthy athletic men between 18 and 40 years old with no musculoskeletal conditions that would interfere with exercise

What does the study involve?

1. Personal data collection
2. A short questionnaire to determine eligibility
3. A blood collection before exercise
4. Performing load-low bilateral knee extensions with or without blood-flow restriction therapy. The decision to do it under blood-flow restriction will be randomly allocated on the day of the study
5. Blood collection 10, 20 and 30 minutes after exercise
6. Analysis of the blood samples

Participation in the study will take only 2 hours. The investigators will cover the participation

costs and laboratory analysis. All participants will be monitored for 72 hours after to record adverse events and health care coverage. All study data will be protected and only accessible to the investigators for 5 years before destruction.

What are the possible benefits and risks of participating?

Patients will benefit from the study by learning and experiencing an exciting exercise modality that can impact their current sporting activities and training and updated blood tests for health screening purposes.

Blood-flow restriction therapy has been deemed safe under medical supervision. The risks are comparable to those of traditional exercise. However, there are few reports of adverse events such as pain or discomfort during exercise, delayed onset muscle soreness, increased heartbeat, increased blood pressure, numbness, bruising, fainting, clot formation, and muscle injury. These risks are negligible following the current standards.

Where is the study run from?

Centro Profesional Las Mercedes, Clínica Santa Sofía, and Laboratorio Avilab in Caracas (Venezuela)

When is the study starting and how long is it expected to run for?

January 2024 to January 2025

Who is funding the study?

The International Society of Arthroscopy, Knee Surgery, and Orthopaedic Sports Medicine (ISAKOS) (USA)

Who is the main contact?

1. Dr Theodorakys Marín, theodorakys.marin@ucv.ve
2. Dra Janet Fermín

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Dr Theodorakys Marín Fermín

ORCID ID

<https://orcid.org/0000-0002-1698-9517>

Contact details

Centro Médico Profesional Las Mercedes. Av. Ppal de Las Mercedes, piso 3, consultorio 37.

Caracas

Venezuela

1060

+58 (0)4143727046

theodorakys.marin@ucv.ve

Additional identifiers

Protocol serial number

001-2024 version

Study information

Scientific Title

Blood flow restriction enhanced platelet-rich plasma: a pilot

Acronym

BFR-PRP

Study objectives

The present study aims to assess platelet-rich plasma (PRP) changes in platelet and leukocyte count, IGF-1, and IL-6 concentration after bilateral low-load knee extensions under blood flow restriction (BFR). The hypothesis is that bilateral low-load knee extensions under BFR will increase platelet and leukocyte count, IGF-1, and IL-6 in PRP prepared after the exercise bout.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 09/02/2024, Comité de Bioética del Grupo Médico Vargas - Clínica Santa Sofía (Av. Ppal. Santa Sofía, Edif. Clínica Santa Sofía, Caracas, 1061, Venezuela; +58 (0)2123355030; sociedadmedicasantasofia@gmail.com), ref: S/N

Study design

Randomized controlled trial

Primary study design

Observational

Study type(s)

Other

Health condition(s) or problem(s) studied

Platelet-rich plasma changes after bilateral low-load knee extensions under blood-flow restriction in the athletic population

Interventions

Before the intervention, participants will have a pre-exercise peripheral vein catheterization, blood sample draw, and PRP preparation for baseline measurements. Each participant will undergo standard venipuncture in the antecubital fossa by a single phlebotomist under sterile conditions for a total blood draw of 15 ml in a BD vacutainer and undergo a single centrifugation at 1500 rpm for 5 minutes. The plasma portion and buffy coat will be separated from the red blood cells, and samples will be sent to the laboratory and divided into two aliquots, one for cell counts (automated cell counter), the other for IGF-1 and IL-6 immunoassays analysis within 6 hours.

The participant will then perform the low-load BFR protocol. The low-load bilateral knee extensions under BFR (using tourniquets at the proximal end of both thighs) will follow the

standard protocol of four sets consisting of 30-15-15-15 repetitions, with 30-second rest intervals at 80% of limb occlusive pressure (calculated using arteria pedis ultrasound) and 30% of 1-RM load (using Holten diagram). Individuals will be randomly assigned to the intervention or control groups (performing the low-load knee extension protocol without BFR) at recruitment (1:1).

A staff physician will monitor the entire exercise protocol and recovery period for safety and adverse events. Once the exercise protocol is completed, participants will be allowed a recovery period (including rest, walking if desired, and fluid intake) before undergoing the consecutive blood draw. The maximum recovery permitted time will be 5 minutes. The subsequent blood draws and PRP processing will be performed identically to the first at 10, 20, and 30 minutes post-intervention.

Intervention Type

Other

Primary outcome(s)

IGF-1 and IL-6 plasmatic concentrations measured by immunoassay analysis at baseline, 10, 20 and 30 minutes after bilateral knee extensions under blood-flow restriction therapy

Key secondary outcome(s)

Platelet and leukocyte plasmatic concentrations measured with an automated cell counter at baseline, 10, 20 and 30 minutes after bilateral knee extensions under blood-flow restriction therapy

Completion date

01/01/2025

Eligibility

Key inclusion criteria

1. Healthy individuals undergoing routine health screening
2. Aged between 18 and 40 years
3. No musculoskeletal conditions that would interfere with exercise

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

40 years

Sex

Male

Key exclusion criteria

1. Systemic inflammatory diseases
2. Cardiovascular risk factors
3. Any blood dyscrasia
4. Tegner Activity scale score <5
5. Under nonsteroidal anti-inflammatory drugs and aspirin treatment within 1 week before testing
6. Previously performed exercises on the testing day

Date of first enrolment

12/05/2024

Date of final enrolment

12/08/2024

Locations**Countries of recruitment**

Venezuela

Study participating centre**Laboratorios Avilab**

6ta Transversal de Altamira con Avenida San Juan Bosco, Edificio Clínica El Avila, Anexo A, Piso 1
Caracas
Venezuela
1060

Study participating centre**Clínica Santa Sofía**

Av. Ppal. Santa Sofía, Edif. Clínica Santa Sofía
Caracas
Venezuela
1061

Study participating centre**Centro Médico Profesional Las Mercedes**

Av. Ppal. de Las Mercedes con calle Mucuchíes, piso 3, consultorio 37.
Caracas
Venezuela
1060

Sponsor information

Organisation

International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine

ROR

<https://ror.org/02427qx15>

Funder(s)

Funder type

Other

Funder Name

International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine

Alternative Name(s)

International Society of Arthroscopy, Knee Surgery & Orthopaedic Sports Medicine, Intl Society of Arthroscopy Knee Surgery and Orthopaedic Sports Med, INT'L SOC OF ARTHROSCOPY KNEE SURG, ISAKOS Society, ISAKOS

Funding Body Type

Government organisation

Funding Body Subtype

Associations and societies (private and public)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and analyzed during the current study will be published as a supplement to the publication of the results.

IPD sharing plan summary

Published as a supplement to the results publication

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
			04/11		

Results article		30/10/2025	/2025	Yes	No
Protocol article		16/01/2025	05/11 /2025	Yes	No
Other files	Informed consent form (in Spanish)		26/04 /2024	No	No
Participant information sheet			22/04 /2024	No	Yes
Participant information sheet	in Spanish		24/04 /2024	No	Yes
Plain English results			04/11 /2025	No	Yes
Protocol file			26/04 /2024	No	No
Statistical Analysis Plan			13/08 /2024	No	No